Drug intelligence / Profile preview

CSL730

Development stage: Discontinued
Lead developer: CSL Behring
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CSL730 (also known as M230) is a novel recombinant trivalent human IgG1 Fc multimer developed by CSL Behring and Momenta Pharmaceuticals. It acts as an immunomodulator by targeting Fc gamma receptor (FcγRs), functioning as an Fc receptor modulator. The drug was designed to provide high potency in modulating immune responses, with the aim of serving as a substitute for intravenous immunoglobulin (IVIG) therapy at lower doses. Its primary indications included autoimmune disorders such as idiopathic thrombocytopenic purpura and skin disorders like epidermolysis bullosa. Development has been discontinued for these indications[1][3][5][7].

Other names: CSL 730CSL730CSL-730M-230M230M 230

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on CSL730.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSL730.

Explore the full profile